This study is currently not recruiting participants.

A Double-Blind Placebo-Controlled Parallel-Group Multicenter Multiregional one year Study to Assess the Efficacy and Safety of Twice daily oral Rifaximin Delayed Release Tablets for Induction of clinical Remission with Endoscopic response at 16 weeks followed by clinical and endoscopic remission at 52 weeks in Subjects with Active Moderate Crohn?s Disease

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to test if taking rifaximin can improve symptoms of active moderate Crohn's disease and maintain that improvement for the duration of study.

Detailed description of study

The purpose of this study is to test if taking rifaximin can improve symptoms of active moderate Crohn's disease and maintain that improvement for the duration of study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Crohn's disease
  • Age: 100 years or below
  • Gender: All
Updated on 02 Apr 2015. Study ID: 1501433357

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team